a real world effectiveness study of pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria (pnh)

Conditions: Paroxysmal Nocturnal Hemoglobinuria

Summary: this is a 36-month, long-term, multicenter, observational study designed to describe the real world effectiveness of pegcetacoplan in patients with pnh. patients meeting the eligibility criteria will be enrolled in the study and followed prospectively for approximately 36 months. patient data will be collected from start of pegcetacoplan treatment to end of follow-up. retrospective data on pegcetacoplan will be captured from the time of pegcetacoplan treatment initiation. pegcetacoplan treatment data will be collected for a minimum of approximately 36 months and up to a maximum of approximately 72 months, including retrospective period depending on when the patient started pegcetacoplan treatment. after pegcetacoplan treatment discontinuation, patients will remain in the study for 8 weeks to capture any aes. the scope of the study is to collect both retrospective and prospective data. baseline is defined as start of pegcetacoplan treatment. the main part of the study will be prospective,collecting data on effectiveness, safety (all aes), patient- and clinician-reported outcomes and health care resource use.

as pegcetacoplan is a new product on the market, with a new mechanism of action, there is an urgent need to provide data to treaters, payers and the pnh community on the real-world usage and effectiveness of pegcetacoplan. this study aims to fill part of that knowledge gap and to add to the knowledge base regarding the use of pegcetacoplan in routine medical practice. another important rationale for this study is to provide information on rbc transfusions and health care resource utilization pre and post pegcetacoplan treatment initiation. the study plans to include approximately 200 patients at 70 sites in europe, middle east, canada and australia. additional countries may be added in the study if necessary. patients meeting the eligibility criteria will be enrolled in the study and followed prospectively for approximately 36 months. patient data will be collected from start of pegcetacoplan treatment to end of follow-up. retrospective data on pegcetacoplan will be captured from the time of pegcetacoplan treatment initiation. pegcetacoplan treatment data will be collected for a minimum of approximately 36 months and up to a maximum of approximately 72 months, including retrospective period depending on when the patient started pegcetacoplan treatment. after pegcetacoplan treatment discontinuation, patients will remain in the study for 8 weeks to capture any aes. patients will come to their routine visits and the available data from each visit will be collected. the scope of the study is to collect both retrospective and prospective data. the main part of the study will be prospective, collecting data on effectiveness, safety, patient- and clinician-reported outcomes and health care resource use. the study will also collect retrospective data before pegcetacoplan treatment start, which will consist of information on pnh treatment, blood transfusions and healthcare resource use. data will be collected for up to 12 months prior to pegcetacoplan treatment start. as patients may have been treated with pegcetacoplan for up to 12 months prior to enrollment, retrospective data may be collected for up to 24 months. this means that the total data collection period including both the retrospective and the prospective part is up to 48 (+/- 3) months.

Eligibility criteria:
inclusion criteria: * patients ≥18 years of age with a documented pnh diagnosis. * patient started routine treatment with pegcetacoplan for pnh up to 12 months before enrollment or prescribed pegcetacoplan at enrollment. decision to initiate treatment shall be made by the treating physician and independently from the decision to include the patient in the study. * patient is willing and able to provide written informed consent to participate in the study in a manner approved by the institutional review board/independent ethics committee and local regulations. exclusion criteria: * enrollment in a concurrent clinical interventional study, or intake of an investigational medicinal product (imp), within three months prior to the start of the current pegcetacoplan treatment. * initiated current treatment with pegcetacoplan in an interventional study.